Proactive Investors - Run By Investors For Investors

Imugene appoints global pharmaceutical executive to its board

Dr. Lesley Russell brings extensive pharmaceutical experience to the board including a number of cancer therapy collaborations with Teva Pharmaceuticals.
table and chairs
Imugene is advancing its promising cancer vaccine pipeline

Imugene Ltd (ASX:IMU) has appointed leading global pharmaceutical executive Dr. Lesley Russell as a non-executive director, effective April 23, 2019.

Dr. Russell has more than 25 years of international operational and leadership experience with a number of established and emerging pharmaceutical companies across multiple therapeutic areas including oncology and haematology.

READ: Imugene well-funded to progress clinical milestones

Her experience has been gained at a number of leading companies including Amgen (NASDAQ:AMGN), Eli Lilly (NASDAQ:LLY), Cephalon Inc (NASDAQ:CEPH) and Teva Pharmacaeuticals (NASDAQ:TEVA).

Dr. Russell is currently a non-executive director of AMAG Pharmaceuticals (NASDAQ:AMAG), Enanta Pharmaceuticals (NASDAQ:ENTA) and Sojournix a privately held biotechnology company.

READ: Imugene presents positive new data validating its human cancer vaccine KEY-Vaxx

Imugene executive chairman Paul Hopper said: “Dr. Lesley Russell’s global industry knowledge and direct experience of oncology drug development and strategic joint ventures will further enhance the board’s skill mix.

“We are delighted she is joining our business and look forward to her contributions as we work to advance our promising cancer vaccine pipeline.”

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies
January 31 2019
Long-term fundamentals remain firmly in the seafood specialist's favour.
Woman touching face
May 01 2019
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use